Brief: Denali Therapeutics And Royalty Pharma Announce $275 Million Royalty Funding Agreement
04/12/2025 14:20
Dec 4 (Reuters) - Denali Therapeutics Inc DNLI.O: DENALI THERAPEUTICS AND ROYALTY PHARMA ANNOUNCE $275 MILLION ROYALTY FUNDING AGREEMENT DENALI THERAPEUTICS INC - ROYALTY PHARMA TO RECEIVE 9.25% ROYALTY ON WORLDWIDE SALES OF TIVIDENOFUSP ALFA FROM DENALI Source text: ID:nGNX37RwwN Further company coverage: DNLI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers